AbbVie's Skyrizi Poised To Enter Packed Psoriasis Market
AbbVie could be looking at near-simultaneous launches for Skyrizi on both sides of the Atlantic after the psoriasis drug – a key future growth driver – got a positive opinion from Europe's regulators some two months before the FDA is due to give its verdict on the interleukin-23 inhibitor.
You may also be interested in...
Countdown To The Allergan Merger, And More From AbbVie’s Q4 Earnings
Despite Humira’s ex-US sales erosion, AbbVie reports strong launches for Skyrizi and Rinvoq, continued growth for hematological oncology franchise, and boasts it has a thriving R&D engine.
AbbVie CEO Upbeat On Skyrizi Commercialization, Raises Financial Guidance
AbbVie’s product pipeline may be delivering just in time to alleviate concerns about loss of exclusivity on its best-selling product, Humira.
AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.